UB-421Innovative AIDS Therapeutic Monoclonal Antibody

Potential Indications

cART substitution, multi-drug resistance, functional cure

Stage

Phase III trial application in Taiwan and Thailand (cART substitution);

US phase IIb/III trial application (multi-drug resistance)

TW phase II clinical trial (functional cure)

Global Prevalence Rate/Patient Number

36.7M (UNAIDS 2016)

Global Market Size

$24B (IMS Health 2016)

  • What Is UB-421

    UB-421 is a monoclonal antibody drug that blocks HIV viral entry.

  • Mechanism

    UB-421 is a viral inhibitor that targets CDR2 domain of CD4 receptor on CD4 T cell surface. UB-421 blocks the entry of HIV into the cells via a competitive inhibition mechanism.

  • Advantages

    1. The affinity of UB-421 to CD4 T cells is 100 times stronger than HIV.
    2. The individual maximal viral load reduction up to 2.25 log10 copies/mL after single administration and up to 3.28 logs from repeated dosing.
    3. Competitive inhibition.
    4. Can neutralize multiple subtypes of HIV.
    5. UB-421 inhibits both cell-to-cell and cell-free transmission of HIV.
    6. Immune modulation.
    7. Potential monotherapy.

UB-621Innovative Anti-HSV Monoclonal Antibody

Indication

Recurrent genital herpes, drug-resistant HSV infection

Stage

US phase II clinical trail IND

Global Prevalence Rate/Patient Number

Two-thirds of the population younger than 50 are carriers of HSV (WHO); Every one of five people in the US is suffering from genital herpes

Global Market Size

$670M in 2023 (GlobalData)

  • What Is UB-621

    UB-621 is an anti-HSV monoclonal antibody drug that provides a solution to recurrent genital herpes and drug-resistant HSV infection.

  • Mechanism

    UB-621 is a fully humanized viral entry inhibitor that recognizes glycoprotein D (gD) of HSV type I and type II.

  • Advantages

    1. The leading antibody drug for HSV infection.
    2. A promising solution to ACV drug-resistant HSV infection.